PMP22 and neuropathy: Our results indicate that a single lumbar intrathecal injection of AAV9-miR871 at early and late stages of the neuropathy, and always after onset, can correct the functional, morphological, and inflammatory abnormalities of CMT1A without causing any apparent side effects.